Precision, Sequencing, and Tolerability in ROS1-Positive Advanced NSCLC

Wade Iams, MD, says adding RNA-based next-generation sequencing (NGS) to DNA-based NGS identifies about 15% more patients with actionable fusions, and urges clinicians to confirm whether the panel they ordered includes RNA at all, since the report rarely makes that obvious.

Wade Iams, MD, says the guidance has changed on what to do when a ROS1 result lands after chemoimmunotherapy has already started.